Fierce Biotech names Mestag Therapeutics as one of its “Fierce 15” Biotech Companies of 2021

September 27, 2021

Cambridge, UK, 27 September 2021 – Mestag Therapeutics (“Mestag”), a breakthrough inflammatory disease and immuno-oncology company, today announced that Fierce Biotech has named it as one of 2021’s Fierce 15 biotechnology companies, designating it as one of the most promising early-stage biotechnology companies in the industry.

“In 2020, we got to celebrate the best and brightest biotechs trying to dig the world out of the pandemic. Speaking with this year’s class of Fierce 15 winners showed us that not even a global pandemic can stop incredible innovations in medicine, and we’re on the cusp of some new breakthrough treatments that have continued apace despite unprecedented disruption last year,” said Annalee Armstrong, Senior Editor of Fierce Biotech. “Slowing down was not an option for our 2021 Fierce 15 winners. From a biotech exploring a new type of viral vector for gene therapies to one trying to crack fibroblasts as a way to target resistant tumors, the Fierce Biotech team heard one thing in common: strong teams of scientists and professionals united in a goal to advance life-changing medicines. We’re proud to showcase this esteemed group of emerging biotechs to the world.”

“We are thrilled to be named among the industry’s most promising new biotech companies. At Mestag we are pioneering new therapeutic advances through our unique understanding of fibroblast populations, and the roles they play in influencing immune effector cells in disease,” said Susan Hill, PhD, Chief Executive Officer of Mestag. “The talented and growing team at Mestag is making rapid strides in developing our platform and building a pipeline of new medicines to address a range of cancers and inflammatory diseases. It is a tremendous honour that our approach and our team have been recognized with this Fierce 15 award.”

The Fierce 15 celebrates the spirit of being “fierce” – championing innovation and creativity, even in the face of intense competition.  This is Fierce Biotech’s 19th annual Fierce 15 selection.  An internationally recognized daily report reaching a network of over 300,000 biotech and pharma industry professionals, Fierce Biotech provides subscribers with an authoritative analysis of the day’s top stories. Every year Fierce Biotech evaluates hundreds of early-stage companies from around the world for its annual Fierce 15 list, which is based on a variety of factors such as the strength of its technology, partnerships, venture backers and a competitive market position.

Mestag’s mission is to develop impactful new medicines for patients by targeting activated fibroblast populations and their role in influencing immune effector cells in disease. Powerful new technologies enable diseased tissues to be analyzed at a single-cell level, and this work has uncovered discrete fibroblast cell sub-populations shared across diseases, acting as “immune sentinels” in perpetuating, and progressing disease. Mestag is progressing a pipeline of first-in-class therapeutics to interrupt fibroblast-mediated effects on immune cells in inflammatory disease and cancer.

ENDS

Enquiries

JW Communications

Julia Wilson

Tel: +44 (0)7818 430877

About Mestag:

Mestag was founded in 2020 by leading investigators and SV Health Investors to develop new medicines for people affected by inflammatory disease and cancer. We develop impactful therapies for patients by targeting activated fibroblast populations and their role in influencing the immune system in disease. Our founding investigators comprise leading experts in inflammatory disease, cancer, computational biology and fibroblast biology Professor Michael Brenner (Brigham and Women’s Hospital and Harvard Medical School), Professor Chris Buckley (Kennedy Institute, University of Oxford), Professor David Tuveson (Cold Spring Harbor Laboratory and President of AACR), Professor Soumya Raychaudhuri (Harvard Medical School and Broad Institute) and Professor Mark Coles (Kennedy Institute, University of Oxford).

The Mestag team is progressing a pipeline of first in class therapeutics to interrupt fibroblast-mediated effects on immune cells in inflammatory disease and immuno-oncology. Mestag is supported by leading global investors SV Health Investors, Johnson & Johnson Innovation – JJDC, Inc., Forbion, GV (formerly Google Ventures) and Northpond Ventures. The company is headquartered in Cambridge, UK.  For more information, please visit www.mestagtx.com.

About Fierce Biotech

Fierce Biotech is the biotech industry’s daily monitor, an email newsletter and web resource providing the latest biotech news, articles, and resources related to clinical trials, drug discovery, FDA approval, FDA regulation, patent news, pharma news, biotech company news and more. More than 300,000 top biopharma professionals rely on Fierce Biotech for an insider briefing on the day’s top stories. Signup is free at www.fiercebiotech.com/signup.